Posters

Safety of dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion

Poster Details

First Author: P.Gouveia PORTUGAL

Co Author(s):    M. Sousa Falcao   S. Penas   V. Rosas   A. Carneiro   F. Falcao Reis                 

Abstract Details



Purpose:

To assess the safety of the dexamethasone implant in the treatment of macular edema (ME) secondary to retinal vein occlusions.

Setting:

Retrospective study conducted at Hospital São João, Porto, Portugal, a tertiary health-care centre.

Methods:

In this study we patients with ME secondary to central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) treated with the dexamethasone implant (Ozurdex®, Allergan Inc, Irvine, CA) from January 2011 through August 2015. Safety assessment included analysis of cataract progression, intra-ocular pressure (IOP) changes, antihypertensive eye drops requirement and/or glaucoma surgery.

Results:

Twenty-four eyes (24 patients) were included in the study, 58% female. Mean age was 66.5 years (49 – 95 years). Thirteen BRVO and 11 CRVO were treated in this series. 75% had history of previous treatment (laser, intravitreal injections or vitrectomy). In six patients (25%) the implant was used as first-line therapy. Twenty patients (83.0%) were phakic in the beginning of the study. Cataract progression was observed in two patients, though none required cataract surgery. Ocular hypertension (IOP>21mmHg) was documented in seven patients (29.1%) following treatment and control was reached with antihypertensive eye drops. A mean 3.53 mmHg elevation of IOP wasn’t statistically significant. The subgroup analysis of BRVO and CRVO did not detect differences in the following parameters: cataract progression, cataract surgery, IOP elevation and hypotensive drug requirement.

Conclusions:

The dexamethasone implant is an important therapeutic tool for ME secondary to retinal vein occlusions. In this series, cataract progression was negligible, though 83% of our patients were phakic. The IOP elevation, observed in 30% of patients, was readily managed with antihypertensive drops.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy